These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19040315)

  • 1. Assessing the safety of new arthritis drugs: are we there yet?
    Suissa S
    J Rheumatol; 2008 Dec; 35(12):2295-7. PubMed ID: 19040315
    [No Abstract]   [Full Text] [Related]  

  • 2. Do all drugs and treatments for rheumatoid arthritis have the same efficacy?
    Weisman MH
    Nat Clin Pract Rheumatol; 2008 Jun; 4(6):298-9. PubMed ID: 18431369
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer.
    Symmons DP; Silman AJ
    Arthritis Rheum; 2004 Jun; 50(6):1703-6. PubMed ID: 15188344
    [No Abstract]   [Full Text] [Related]  

  • 4. Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis.
    Hudson M; Suissa S
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):805-10. PubMed ID: 20535791
    [No Abstract]   [Full Text] [Related]  

  • 5. The British Society for Rheumatology Biologics Register: 6 years on.
    Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
    Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
    [No Abstract]   [Full Text] [Related]  

  • 6. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?
    Robinson WH; Genovese MC; Moreland LW
    Arthritis Rheum; 2001 Sep; 44(9):1977-83. PubMed ID: 11592357
    [No Abstract]   [Full Text] [Related]  

  • 7. Malignancy and biologic therapy in rheumatoid arthritis.
    Askling J; Bongartz T
    Curr Opin Rheumatol; 2008 May; 20(3):334-9. PubMed ID: 18388527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries.
    Nasir A; Greenberg JD
    Bull NYU Hosp Jt Dis; 2007; 65(3):178-81. PubMed ID: 17922666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis.
    Smolen JS; Aletaha D
    Nat Clin Pract Rheumatol; 2008 Jun; 4(6):296-7. PubMed ID: 18461061
    [No Abstract]   [Full Text] [Related]  

  • 10. Interpreting registry-derived drug studies: does societal context matter?
    Kremer JM; Greenberg J
    Arthritis Rheum; 2009 Nov; 60(11):3155-7. PubMed ID: 19877064
    [No Abstract]   [Full Text] [Related]  

  • 11. Perioperative management of patients with rheumatoid arthritis treated with TNF-alpha blocking agents.
    Goupille P; Pham T; Sibilia J; Mariette X
    Semin Arthritis Rheum; 2007 Dec; 37(3):202-3; author reply 203. PubMed ID: 17570470
    [No Abstract]   [Full Text] [Related]  

  • 12. Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumour necrosis factor therapy.
    Winthrop KL; Furst DE
    Ann Rheum Dis; 2010 Oct; 69(10):1735-7. PubMed ID: 20858622
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elective orthopedic surgery and perioperative DMARD management: many questions, fewer answers, and some opinions..
    Bongartz T
    J Rheumatol; 2007 Apr; 34(4):653-5. PubMed ID: 17407223
    [No Abstract]   [Full Text] [Related]  

  • 15. Do antitumor necrosis factor agents increase the risk of postoperative orthopedic infections?
    Pappas DA; Giles JT
    Curr Opin Rheumatol; 2008 Jul; 20(4):450-6. PubMed ID: 18525360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Guidelines in RA treatment: concepts on safety and recommendations using anti-TNF-alpha inhibitors. Grupo de Estudio de Nuevas Terapias de Enfermedades reumáticas (GENTE)].
    Díaz-Jouanen E; Abud-Mendoza C; Garza-Elizondo MA; Medrano-Ramírez G; Burgos-Vargas R; Orozco-Alcalá JJ; Pacheco-Tena CF; Pineda C; Pozos-Espíndola JC; Ramos-Niembro F; Robles-San-Román M; Santana-Sahagún JE;
    Rev Invest Clin; 2009; 61(3):252-66. PubMed ID: 19736814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebral MRI is necessary in patients with rheumatoid arthritis and uveitis before undergoing therapy with TNF-alpha blocking agents.
    Limmroth V; Thimm C; Hudde T; Fuchsluger T; Wanke I
    Rheumatology (Oxford); 2005 Nov; 44(11):1373. PubMed ID: 16244102
    [No Abstract]   [Full Text] [Related]  

  • 18. Tuberculosis in the cytokine era: what rheumatologists need to know.
    Hamilton CD
    Arthritis Rheum; 2003 Aug; 48(8):2085-91. PubMed ID: 12905459
    [No Abstract]   [Full Text] [Related]  

  • 19. Infectious complications of biologic agents.
    Martin-Mola E; Balsa A
    Rheum Dis Clin North Am; 2009 Feb; 35(1):183-99. PubMed ID: 19481004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease modifying treatment and elective surgery in rheumatoid arthritis: the need for more data.
    Jain A; Maini R; Nanchahal J
    Ann Rheum Dis; 2004 May; 63(5):602-3. PubMed ID: 15082498
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.